{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:32:20Z","timestamp":1788255140755,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003983","name":"National Headache Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014832","name":"American Headache Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AG030857"],"award-info":[{"award-number":["K23AG030857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23NS05140901A1"],"award-info":[{"award-number":["K23NS05140901A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23NS47256"],"award-info":[{"award-number":["K23NS47256"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PO1 AG03949"],"award-info":[{"award-number":["PO1 AG03949"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PO1AG027734"],"award-info":[{"award-number":["PO1AG027734"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AG022374-06A2"],"award-info":[{"award-number":["RO1AG022374-06A2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AG025119"],"award-info":[{"award-number":["RO1AG025119"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AG034119"],"award-info":[{"award-number":["RO1AG034119"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1AG12101"],"award-info":[{"award-number":["RO1AG12101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jns.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T02:31:28Z","timestamp":1371609088000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"title":["OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline"],"prefix":"10.1016","volume":"331","author":[{"given":"Stephen D.","family":"Silberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena K.","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sirimanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"DeGryse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Turkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jns.2013.05.003_bb0005","first-page":"9","article-title":"The International Classification of Headache Disorders, 2nd edition","volume":"24","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.05.003_bb0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","article-title":"New appendix criteria open for a broader concept of chronic migraine","volume":"26","author":"Olesen","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1526-4610.2003.03068.x","article-title":"Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine","volume":"43","author":"Bigal","year":"2003","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1526-4610.2009.01369.x","article-title":"Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study","volume":"49","author":"Munakata","year":"2009","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0035","first-page":"S26","article-title":"Chronic refractory headache","volume":"43","author":"Mathew","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.05.003_bb0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","article-title":"Medication-overuse headache: a worldwide problem","volume":"3","author":"Diener","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jns.2013.05.003_bb0045","first-page":"145","article-title":"Migraine chronification\u2014concept and risk factors","volume":"8","author":"Bigal","year":"2009","journal-title":"Discov Med"},{"key":"10.1016\/j.jns.2013.05.003_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-2982.2004.00691.x","article-title":"Transformed migraine and medication overuse in a tertiary headache centre\u2014clinical characteristics and treatment outcomes","volume":"24","author":"Bigal","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1212\/WNL.61.2.154","article-title":"Chronic daily headache: is analgesic overuse a cause or a consequence?","volume":"61","author":"Lipton","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.05.003_bb0060","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-2982.2008.01711.x","article-title":"Management of medication overuse headache: 1-year randomized multicentre open-label trial","volume":"29","author":"Hagen","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0070","series-title":"New advances in headache research","first-page":"255","article-title":"Chronic headaches associated with analgesics and\/or ergotamine abuse: a clinical survey of 434 consecutive out-patients","author":"Schoenen","year":"1989"},{"key":"10.1016\/j.jns.2013.05.003_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-2982.2004.00789.x","article-title":"Medication overuse headache: rates and predictors for relapse in a 4-year prospective study","volume":"25","author":"Katsarava","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1468-2982.2005.00878.x","article-title":"The International Classification of Headache Disorders, 2nd Edition (ICHD-II)\u2014revision of criteria for 8.2 medication-overuse headache","volume":"25","author":"Silberstein","year":"2005","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0333102411425867","article-title":"Detoxification for medication overuse headache is not necessary","volume":"32","author":"Diener","year":"2012","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0095","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0105","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","article-title":"Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults","volume":"28","author":"Silberstein","year":"2008","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: the HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jns.2013.05.003_bb0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jclinepi.2005.05.010","article-title":"Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test","volume":"59","author":"Coeytaux","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jns.2013.05.003_bb0140","series-title":"The HIT-6\u2122: a user's guide","author":"Bayliss","year":"2002"},{"key":"10.1016\/j.jns.2013.05.003_bb0145","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11136-007-9217-1","article-title":"Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment","volume":"16","author":"Cole","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jns.2013.05.003_bb0150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00019053-199813060-00007","article-title":"MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure","volume":"13","author":"Jhingran","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jns.2013.05.003_bb0155","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1468-2982.2009.01852.x","article-title":"Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1","volume":"29","author":"Cole","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0160","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1526-4610.2007.00950.x","article-title":"The impact of topiramate on health-related quality of life indicators in chronic migraine","volume":"47","author":"Dodick","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.jns.2013.05.003_bb0170","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11916-011-0188-0","article-title":"ICHD-3: what changes do we need regarding migraine?","volume":"15","author":"Manzoni","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.jns.2013.05.003_bb0175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1468-2982.2009.01859.x","article-title":"Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse","volume":"29","author":"Diener","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jns.2013.05.003_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1526-4610.2009.01481.x","article-title":"Headache prophylaxis with BoNTA: patient characteristics","volume":"50","author":"Silberstein","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.jns.2013.05.003_bb0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1468-2982.2000.00117.x","article-title":"Guidelines for controlled trials of drugs in migraine: second edition","volume":"20","author":"Tfelt-Hansen","year":"2000","journal-title":"Cephalalgia"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:42:48Z","timestamp":1758382968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X13002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0022510X13002104"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2013.05.003","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}